1834 Investment Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-233
Closed -$7K 211
2022
Q2
$7K Hold
233
﹤0.01% 392
2022
Q1
$11K Hold
233
﹤0.01% 345
2021
Q4
$14K Hold
233
﹤0.01% 356
2021
Q3
$17K Hold
233
﹤0.01% 353
2021
Q2
$22K Hold
233
﹤0.01% 352
2021
Q1
$21K Hold
233
﹤0.01% 318
2020
Q4
$22K Hold
233
﹤0.01% 310
2020
Q3
$15K Buy
+233
New +$13.7K ﹤0.01% 322

Other funds holding ARKG

1834 Investment Advisors's ARKG Position: Q3 2022 in Review

1834 Investment Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q3 2022, closing a stake of 233 shares — an estimated $7K sold.

1834 Investment Advisors first reported a position in ARKG in Q3 2020 and held it in 8 quarters. The position peaked at $22K in Q2 2021. 311 funds tracked by Wall St. Rank hold ARKG as of Q3 2022.

  • 1834 Investment Advisors reported no remaining ARK Genomic Revolution ETF position as of Q3 2022 after selling out during the quarter.
  • 1834 Investment Advisors sold 233 ARK Genomic Revolution ETF shares in Q3 2022, an estimated $7K.
  • 1834 Investment Advisors first reported a position in ARK Genomic Revolution ETF in Q3 2020 and held it in 8 quarters.
  • 1834 Investment Advisors's ARK Genomic Revolution ETF position peaked at $22K in Q2 2021.
  • 311 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2022.

Based on 1834 Investment Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.